Werbung
Werbung

KYMR

KYMR logo

Kymera Therapeutics, Inc. Common Stock

74.71
USD
Gesponsert
-0.27
-0.36%
09. Jan., 15:59 UTC -5
Geschlossen
exchange

Nach-Markt

74.71

0.00
0.00%

KYMR Ergebnisberichte

Positives Überraschungsverhältnis

KYMR übertreffen die 6 der letzten 21Schätzungen.

29%

Nächster Bericht

Datum des nächsten Berichts
25. Feb. 2026
Estimate for Q4 25 (Revenue/ EPS)
$15.47M
/
-$0.81
Implizierte Änderung von Q3 25 (Revenue/ EPS)
+459.71%
/
-13.83%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
+109.23%
/
-7.95%

Kymera Therapeutics, Inc. Common Stock earnings per share and revenue

On 04. Nov. 2025, KYMR reported earnings of -0.94 USD per share (EPS) for Q3 25, missing the estimate of -0.82 USD, resulting in a -14.63% surprise. Revenue reached 2.76 million, compared to an expected 19.33 million, with a -85.70% difference. The market reacted with a +0.32% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 25 analysts forecast an EPS of -0.81 USD, with revenue projected to reach 15.47 million USD, implying an decrease of -13.83% EPS, and increase of 459.71% in Revenue from the last quarter.
FAQ
For Q3 2025, Kymera Therapeutics, Inc. Common Stock reported EPS of -$0.94, missing estimates by -14.63%, and revenue of $2.76M, -85.7% below expectations.
The stock price moved up 0.32%, changed from $59.72 before the earnings release to $59.91 the day after.
The next earning report is scheduled for 25. Feb. 2026.
Based on 25 analysts, Kymera Therapeutics, Inc. Common Stock is expected to report EPS of -$0.81 and revenue of $15.47M for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung